Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.

@article{Hijazi2002ContributionOC,
  title={Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.},
  author={Youssef Hijazi and Roselyne Boulieu},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2002},
  volume={30 7},
  pages={
          853-8
        }
}
  • Y. Hijazi, R. Boulieu
  • Published 1 July 2002
  • Biology, Chemistry, Medicine
  • Drug metabolism and disposition: the biological fate of chemicals
Ketamine is a widely used drug for its anesthetic and analgesic properties; it is also considered as a drug of abuse, as many cases of ketamine illegal consumption were reported. Ketamine is N-demethylated by liver microsomal cytochrome P450 into norketamine. The identification of the enzymes responsible for ketamine metabolism is of great importance in clinical practice. In the present study, we investigated the metabolism of ketamine in human liver microsomes at clinically relevant… 
View on PubMed
dmd.aspetjournals.org
248 Citations
Highly Influential Citations
13
Background Citations
95
Methods Citations
5
Results Citations
4

Figures and Tables from this paper

248 Citations

The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro
TLDR
Results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP 2B6*6 allele on enzyme-ketamine binding and catalytic activity.
Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro.
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
TLDR
These results show that while the CYP2B6*6 polymorphism results in diminished ketamines metabolism in vitro, this allelic variant did not affect single, low-dose ketamine metabolism, clearance, and pharmacokinetics in vivo.
Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes
TLDR
The formation rate of DLOP showed biphasic kinetics, suggesting the involvement of multiple P450 isoforms, and among them, CYP2C8 and CYP3A4 may play a crucial role in LOP metabolism at the therapeutic concentrations of LOP.
Role of the equine CYP3A94, CYP3A95 and CYP3A97 in ketamine metabolism in presence of medetomidine, diazepam and methadone studied by enantioselective capillary electrophoresis.
Effects of medetomidine and its active enantiomer dexmedetomidine on N‐demethylation of ketamine in canines determined in vitro using enantioselective capillary electrophoresis
TLDR
S‐ketamine combined with dexmedetomidine should be the best option for canines and the enantioselective CE assay with highly sulfated γ‐cyclodextrin as chiral selector is an effective tool for determining kinetic and inhibition parameters of metabolic pathways.
Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches.
TLDR
Apparent substrate binding affinity was the major consequence of halogen substitution and the major determinant of N-demethylation of ketamine and analogs and may be the simplest design criteria to use when considering similar compounds and CYP2B6 affinity.
Cytochrome P450 2B6: function, genetics, and clinical relevance
TLDR
CYP2B6 is one of the most polymorphic CYP genes in humans with over 100 described SNPs, numerous complex haplotypes and distinct ethnic and racial frequencies and the main characteristics of clinical relevance are summarized.
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
TLDR
Scaling of in vitro intrinsic clearance values from expressed enzymes to the whole liver using a relative abundance approach indicated that either CYP3A4 alone or CYP4 and CYP2B6 are the major contributors to R-138727 formation, which is expected to substantially inhibit the P450-mediated metabolism of coadministered drugs.
...
...

References

SHOWING 1-10 OF 35 REFERENCES
Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
TLDR
CYP2B6 mainly mediates the N-demethylation of (R)- and (S)-ketamine in human liver microsomes at therapeutic concentrations (5 microM) and the results suggest that the high affinity/low capacity enzyme in human Liver Microsomes is mediated by CYP2B 6, and the low affinity/high capacity enzyme ismediated by CYC2C9 and CYP3A4.
Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.
TLDR
It is concluded that human CYP1A2 expressed in yeast is a powerful tool to predict and to quantify drug-drug interactions in man.
Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
TLDR
It is indicated that CYP2C19 is a primary determinant of S-mephenytoin 4'-hydroxylation and low-Km omeprazole 5-hydroxyation in human liver and an efficient catalyst of tolbutamide metabolism.
Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes.
TLDR
The view that the roles of individual CYP enzymes in the oxidation of xenobiotic chemicals in human liver microsomes could be predicted by kinetic parameters of individual Cytochrome P-450 enzymes and by the levels of each of the CYP enzyme in livermicrosomes of human samples is supported.
Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism.
TLDR
Spectral studies showed that DMED interacted with microsomal cytochrome P-450 to elicit a Type II binding spectrum, and LMED, although pharmacologically inactive, had a greater inhibitory effect than DMED on racemic ketamine and ketamine enantiomer demethylation at therapeutic concentrations.
Metabolism of ketamine stereoisomers by human liver microsomes.
TLDR
To characterize ketamine racemate and enantiomer metabolism by human liver and to test the hypothesis that differences in hepatic ketamine enantiomers metabolism can account for observed differences in ketamineEnantiomer pharmacokinetics, it is found that S(+) ketamine exhibits a greater clearance and faster anesthetic recovery compared to the racemate.
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
TLDR
Since its inhibition is very potent and has a broad "window of selectivity," omeprazole seems to be a useful, selective inhibitor of CYP2C19, and lansoprazole may be the more important in vitro inhibitor of CyP2D6.
Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics.
TLDR
In microsomes from untreated male rats, orphenadrine failed to significantly inhibit any of the major pathways of P-450-associated androstenedione metabolism, and appeared to be a potent mixed (competitive/noncompetitive)-type inhibitor ofP-450 PB-B/D-associated pentoxyresorufin O-depentylation.
Further characterization of the expression in liver and catalytic activity of CYP2B6.
TLDR
The highly specific MAb 49-10-20 was used to provide further confirmation that S-mephenytoin N-demethylation to nirvanol is a CYP2B6 selective probe and some, but not all substrates of CYP1B6 demonstrate autoactivation.
Selective inhibitors of cytochromes P450.
TLDR
The identification of isoform-selective, nontoxic inhibitors of individual human cytochromes P450 raises the real possibility of modulation of human drug metabolism for therapeutic purposes.
...
...